Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II lenvatinib + carboplatin + pemetrexed + pembrolizumab for pretreated EGFR-mutant non-squamous NSCLC
jRCT2031220147Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib in Non-small cell lung cancer (NS-NSCLC), sponsored by Merck & Co. Primary endpoint: Objective response rate. Started Jul 2022; status: active, not recruiting.
02
Drugs
lenvatinib
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on jRCT2031220147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220147.